numerous pulmonary nodules, and a soft tissue lesion in her right thigh. A lung biopsy confirmed the diagnosis of alveolar soft part sarcoma. The patient underwent total resection of the brain metastasis with subsequent enrollment in clinical trial of cediranib. Treatment was discontinued after 5 months due to central nervous system (CNS) disease progression. The patient then underwent resection of the largest brain metastasis and a large mediastinal metastasis. This was followed by stereotactic radiosurgery of three brain lesions with palliative surgical resection of the primary thigh mass. The pahttps://doi
tient also required urgent surgery for ileocolic intussusception secondary to a small bowel metastatic burden. Patient was treated with cabozantinib (off-label) but demonstrated continued disease progression. This required palliative radiation to brain, soft tissue, bone, pancreas, and renal masses, as well as a repeat small bowel resection for enlarging metastases. After 12 months of treatment with cabozantinib, the patient had turned 15-years-old and therefore became eligible for enrollment in an expanded access program for trabectedin. She had new brain metastases identified after 6 weeks, and therefore trabectedin was discontinued. Subsequently, the i nstitutional review board at Oregon Health and Science University, Genentech, and the Federal Drug Administration, approved an individual investigational new drug protocol for the patient to receive MPDL3280 (Atezolizumab), a monoclonal anti-programmed death ligand-1 (anti-PDL1) antibody. Informed consent was obtained from the patient and her parents. MPDL3280 was administered at a dose of 15 mg/kg IV every 21 days. Treatment was complicated by repeated hospital admissions for partial small bowel obstructions that were successfully managed without surgical intervention. Magnetic resonance imaging (MRI) of the brain and CT of the chest, abdomen, and pelvis after 8 weeks of treatment demonstrated a mixed response but overall stable disease by Response Evaluation Criteria in Solid Tumors (RECIST). After six doses, she began to experience worsening headaches. Brain MRI confirmed enlargement of multiple brain metastases, most notably in the right temporal lobe ( Fig. 1 A-D) and right cerebellum, with extensive surrounding edema and 5-mm midline shift. Nineteen months prior, the temporal lobe lesion had been treated to 30 Gy and 5 months prior, to 20 Gy. The cerebellar lesion had been treated 13 months prior to 20 Gy. The patient then underwent uncomplicated diagnostic and therapeutic right temporal and cere- bellar craniotomies for resection of these two lesions with 3 days of corticosteroids administered perioperatively. Upon pathologic review, no viable tumor was identified. The surgical specimens contained primarily necrotic tissue with extensive lymphocytic infiltrate as denoted by histology results of increase CD8 staining post-treatment with MPDL3280 ( Figs. 1 E and F). Concurrent RECIST stable systemic metastatic disease was demonstrated in lesions in lung, spleen, and pancreas during treatment ( Fig. 2 ) .
Discussion
PDL-1 release by tumor cells has been shown to inhibit immune response to the tumor. Ligand modulation therapy can enhance lymphocyte activation and engagement of the immune response toward tumor tissue [1] . Flair inflammatory response and pseudoprogression during immune therapy targeting PD-1 and PDL-1 has been reported in nonsmall cell lung cancer as well as CNS metastatic melanoma treatment [2] [3] [4] . These studies have also questioned the standard RESIST 1.1 criteria for clinical decision making for disease progression during use of immune therapy. Developing new strategies when CNS pseudoprogression may be present during mixed systemic response is essential for therapeutic decisions. The case presented here demonstrates pseudoprogression similar to previous reports describing treatment of melanoma with ipilimumab, a monoclonal antibody against cytotoxic Tlymphocyte-associated antigen-4, with initial increased size of systemic tumor lesions that were subsequently confirmed by biopsy as inflammatory cell infiltrates and necrosis [5] . Results for treatment with the PD-1 inhibitor pembrolizumab have also shown disease progression by MRI, in which subsequent histopathology demonstrated inflammatory response to treatment [4] . Currently, rates of CNS metastatic disease pseudoprogression in the context of systemic stable or regressing lesions, as determined by RESIST, are unknown [2] . This is due in part to limited clinical trials that included CNS metastatic disease. In addition, there are suggestions of variable responses likely related to bioavailability of agents or T-cells in CNS lesion microenvironments [6, 7] . To our knowledge, there are no previously published case reports of pseudoprogression involving alveolar soft part sarcoma CNS metastasis treated with MPDL3280 (Atezolizumab). The current literature provides limited data to better delineate expected occurrence rates of mixed systemic response to therapy in the context of CNS pseudoprogression of metastatic disease.
Immune checkpoint inhibitors are utilized in an increasing number of clinical trials for a variety of metastatic disease targets including newly Food and Drug Administration approved targets. Furthermore, there are a growing number of case reports of CNS metastases associated with melanoma and lung cancer, in which CNS pseudoprogression was confirmed by histopathology. These cases involved use of several immune check point inhibitors, such as PD-1 and PDL-1 and T-cell mediated immune therapy CTLA4 antibodies. Currently, newly revised RECIST 1.1 and irRECIST (immune related response RECIST) criteria for validating timeline windows for expected pseudoprogression in metastatic CNS lesions, as well as expected rates of overall occurrence, are not well developed [2, 8] . The CNS lesion microenvironment is thought to have an unknown component for predicted response and response time during immune therapy. CNS bioavailability of PD-1 and PDL-1 is still unknown. This may be related in part to varying levels of blood brain barrier disruption for each metastatic disease type [7, 9] . Largely, pseudoprogression diagnosis has been reliant on retrospective histopathology in most case reports, limiting its value collectively for use in treatment decisions.
To our knowledge, the present case is the only case involving PDL-1 treatment of pediatric metastatic alveolar soft part sarcoma demonstrating CNS pseudoprogression with stable or regression of diffuse systemic disease ( Fig. 1 and Fig. 2 ) . It revisits an ongoing question for use of contrast MRI-based imaging to determine treatment response in trial immune therapies. Use of contrast-enhanced MRI and diffusion-based imaging in disease progression with other therapies such as resection, chemotherapy, and radiotherapy remains a challenge for identifying post-treatment inflammatory reactions for continuation of treatment decisions [10] . There is utility of diffusion-weighted imaging for delineating disease progression vs inflammatory reaction for gliomas [11] . However, varying cell types in metastatic disease and heterogeneous lesion environments would make generalization of these principles inappropriate until specific data exist for each type of metastatic disease [12] . The current RECIST 1.1 and irRECIST mainly rely on imaging demonstrating lesion size progression beyond recommended time frames as it pertains to data from chemoradiative paradigms to evaluate the possibility of pseudoprogression.
Currently, application of RECIST criteria remains difficult with the growing utilization of immune therapy agents, due to lack of data from controlled studies for determining what a reliable response window should be to suggest pseudoprogression. Perhaps, in the near future, perfusion MRI (rCBV) (relative cerebral blood volume) and dynamic susceptibility contrast perfusion can play a larger role in criteria for determining metastatic CNS disease progression, along with PET (positron emission tomography) imaging using neutral amino acid transport metabolism, to help delineate inflammatory response from disease progression [13, 14] .
